In This Section

Program

Please note that this meeting will take place as an in-person event in Los Angeles and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

Keynote speakers

  • Michael Birnbaum, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
  • Pamela J. Björkman, California Institute of Technology, Pasadena, California
  • Mark M. Davis, Stanford Hospital, Stanford, California
  • Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
  • Elaine R. Mardis, Nationwide Children’s Hospital, Columbus, Ohio
  • Tak W. Mak, University of Toronto, Toronto, Ontario, Canada
  • Alexander Marson, University of California, San Francisco, California
  • Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
  • Ton N. Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands
  • E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

Session topics

  • Beyond conventional cell therapy: Emerging technologies for precision immunotherapy
  • Cancer vaccines
  • Defining actionable tumour antigens for cancer immunotherapy
  • Generative design of immune receptors
  • How tissues shape antitumor immunity and immunotherapy response
  • Immune cell interactions in the TME
  • In vivo engineering toolkit
  • Maximizing manufacturability and patient access to cell-based therapies for cancer
  • Mechanisms of response and resistance: Towards more effective immunotherapies
  • Measuring TCR recognition of antigen at scale
  • New advances in TIL therapy
  • Non-MHC-restricted anti-tumour immunity
  • Pain and neuro-immune axis in cancer
  • Precision targets for solid tumors: Neoantigens, fusion-driven antigens, and the dark genome
  • Protein design in I-O
  • Rewiring T cell signaling: Synthetic biology for discovery and therapy
  • Rewriting T cell fate: Epigenetic control of stemness and exhaustion
  • T cell engagers operationalization narrative
  • The myeloid-stromal connection in tumor immunity and therapy resistance
  • The tumor glycocalyx: A new frontier in cancer immunotherapy